Health Dictionary Find a Doctor

Practolol

{{Drugbox | Verifiedfields = changed | verifiedrevid = 464212885 | IUPAC_name = (RS)-N-{4-[2-hydroxy-3-(isopropylamino)propoxy]phenyl}acetamide | image = Practolol structure.png | width = 250

| tradename =

| CASNo_Ref =  ☑Y | CAS_number_Ref =  ☑Y | CAS_number = 6673-35-4 | ATC_prefix = C07 | ATC_suffix = AB01 | PubChem = 4883 | IUPHAR_ligand = 555 | DrugBank_Ref =  ☑Y | DrugBank = DB01297 | ChemSpiderID_Ref =  ☑Y | ChemSpiderID = 4715 | UNII_Ref =  ☑Y | UNII = SUG9176GRW | KEGG_Ref =  ☒N | KEGG = D05587 | ChEBI_Ref =  ☑Y | ChEBI = 258351 | ChEMBL_Ref =  ☑Y | ChEMBL = 6995

| C=14 | H=22 | N=2 | O=3 | molecular_weight = 266.336 g/mol | smiles = O=C(Nc1ccc(OCC(O)CNC(C)C)cc1)C | InChI = 1/C14H22N2O3/c1-10(2)15-8-13(18)9-19-14-6-4-12(5-7-14)16-11(3)17/h4-7,10,13,15,18H,8-9H2,1-3H3,(H,16,17) | InChIKey = DURULFYMVIFBIR-UHFFFAOYAT | StdInChI_Ref =  ☑Y | StdInChI = 1S/C14H22N2O3/c1-10(2)15-8-13(18)9-19-14-6-4-12(5-7-14)16-11(3)17/h4-7,10,13,15,18H,8-9H2,1-3H3,(H,16,17) | StdInChIKey_Ref =  ☑Y | StdInChIKey = DURULFYMVIFBIR-UHFFFAOYSA-N }}

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Practolol (Eraldin, Dalzic, Praktol, Cardiol, Pralon, Cordialina, Eraldina, Teranol) is a selective beta blocker that has been used in the emergency treatment of cardiac arrhythmias. Practolol is no longer used as it is highly toxic despite the similarity of its chemical formula to propranolol. After its introduction, keratoconjunctivitis sicca, conjunctival scarring, fibrosis, metaplasia, and shrinkage developed in 27 patients as an adverse reaction to practolol. Rashes, nasal and mucosal ulceration, fibrous or plastic peritonitis, pleurisy, cochlear damage, and secretory otitis media also occurred in some cases. Three patients suffered profound visual loss though most retained good vision. Symptoms and signs improved on withdrawal of the drug, but reduction of tear secretion persisted in most patients. (British Medical Journal, March 15, 1975)

Side Effects

Side effects are similar to those of other beta blockers, such as bronchoconstriction, cardiac failure, cold extremities, fatigue and depression, hypoglycaemia.[1]

Furthermore, chronic use of practolol may cause oculomucocutaneous syndrome,[1] a severe syndrome whose signs include conjunctivitis sicca and psoriasiform rashes, otitis and sclerosing serositis. This syndrome has not been observed with other such beta blockers.[2]

Ban

This drug has been withdrawn from the market in India due to Oculomucocutaneous Syndrome.[3]

Scientific information / studies
General information

References

  1. 1.0 1.1 Rod Flower; Humphrey P. Rang; Maureen M. Dale; Ritter, James M. (2007). Rang & Dale’s pharmacology. Edinburgh: Churchill Livingstone. ISBN 0-443-06911-5.
  2. rxmed.com > Nadolol Retrieved on July, 2010.
  3. “Drugs banned in India”. Central Drugs Standard Control Organization, Dte.GHS, Ministry of Health and Family Welfare, Government of India. Retrieved 2013-09-17.

© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH